CCO Treatment Updates
Case Debates With the Experts: Applying the Updated Practice Guidelines to the Management of Hepatitis B
Interactive Case Challenges
Management of a Treatment-Naive, HBeAg-Positive, Asian American Patient
|
Program Director: Norah Terrault, MD, MPH
|
|
Jules L. Dienstag, MD, reviews the factors involved in selecting the optimal treatment in patients seeking first-line therapy for hepatitis B.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount the treatment criteria for determining when to begin therapy in an HBeAg-positive patient
- Discuss the clinical data regarding the agents available to treat chronic hepatitis B
- Summarize factors that determine how long one should continue therapy after seroconversion in HBeAg-positive patients
|
Management of an HBeAg-Positive Patient on Active Antiviral Therapy Who Has Failed to Achieve a Primary Response
|
Program Director: Norah Terrault, MD, MPH
- Nezam H. Afdhal, MD, FRCPI
|
|
|
Nezam H. Afdhal, MD, FRCPI, reviews management strategies for an HBeAg-positive Asian patient with chronic HBV infection.
Learning Objectives
Upon completion of this activity, participants should be able to:
- List the definitions of nonresponse and resistance in hepatitis B and strategies for identifying these response patterns
- Describe the AASLD guideline recommendations for management of primary nonresponse and discuss the merits of each strategy
- Summarize how continued treatment during suboptimal response relates to antiviral resistance rates
|
Management of an HBeAg-Negative Patient With Lamivudine Resistance
|
Program Director: Norah Terrault, MD, MPH
- Emmet B. Keeffe, MD, MACP
|
|
|
Emmet B. Keeffe, MD, MACP, describes treatment strategies for managing emergence of lamivudine resistance in a patient with HBeAg-negative chronic hepatitis B.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recall the optimal treatment strategies for HBeAg-negative chronic hepatitis B
- Discuss how the initial treatment strategies for HBeAg-negative chronic hepatitis B can affect future treatment options
- Summarize management strategies for patients who have resistance toward 1 or more antiviral agents
|
CCO Slidesets
Debate: Nucleos(t)ide Analogues vs Peginterferon in Treatment-Naive HBeAg-Positive Patients
 |
|
Robert P. Perrillo, MD, and Jules L. Dienstag, MD, debate the use of peginterferon vs nucleos(t)ide analogues as first-line therapy for HBeAg-positive hepatitis B patients.
Format: Microsoft PowerPoint (.ppt) |
File size: 627 KB
|
Debate: What Is the Best Rescue Strategy for the Management of Primary Nonresponse: Switch or Add?
 |
|
Robert G. Gish, MD, and Nezam H. Afdhal, MD, FRCPI, debate the optimal strategy for management of hepatitis B patients with primary nonresponse.
Format: Microsoft PowerPoint (.ppt) |
File size: 588 KB
|
Debate: What Is the Optimal Management Strategy for Lamivudine Resistance in HBeAg-Negative Patients?
 |
|
Robert G. Gish, MD, and Robert P. Perrillo, MD, evaluate the best strategies for managing lamivudine resistance in patients with hepatitis B.
Format: Microsoft PowerPoint (.ppt) |
File size: 680 KB
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|